论文信息 - Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. - 字舞流文

Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.

A. Tolcher | A. Patnaik | M. Garrett | T. Yap | S. Heaton | J. D. de Bono | R. Baird | L. Delgado | A. Biondo | D. Sullivan | L. Lupinacci | S. Blackman | A. Taylor | K. Papadopoulos | I. Fearen | S. Decordova | L. Yan | M. Tall